References · updated 27 October 2026

Reference Library

Every citation used across this site, linked to a durable source — plus an honest note about the evidence that does not exist.

Written and reviewed by the EyeFortin-Reviews.com editorial team. Last updated 27 October 2026. See our editorial policy and evidence policy.

The source library behind this site. Every reference below is linked to a durable location — a PubMed record for the paper, or the issuing agency’s own page. We cite ingredient and background research only; no published trial has tested the finished EyeFortin formula, and we do not imply otherwise.

Product and regulatory sources

The primary sources for the product itself are the current 60 mL label (transcribed on the supplement facts page) and the vendor’s published pricing, shipping and refund terms, as checked on 27 October 2026. FDA guidance on supplement labelling and the DSHEA framework is linked below.

Research references

References

  1. Froger N, Moutsimilli L, Cadetti L, et al. Taurine: the comeback of a nutraceutical in the prevention of retinal degenerations. Progress in Retinal and Eye Research. 2014;41:44–63. Source
  2. Arfuzir NN, Agarwal R, Iezhitsa I, et al. Taurine protects against retinal and optic nerve damage induced by endothelin-1 in rats via antioxidant effects. Neural Regeneration Research. 2018;13(11):2014–2021. Source
  3. Jung KI, Kim YC, Park CK. Dietary niacin and open-angle glaucoma: the Korean National Health and Nutrition Examination Survey. Nutrients. 2018;10(4):387. Source
  4. Kamanna VS, Kashyap ML. Mechanism of action of niacin. American Journal of Cardiology. 2008;101(8A):20B–26B. Source
  5. Naber M, Hommel B, Colzato LS. Improved human visuomotor performance and pupil constriction after choline supplementation in a placebo-controlled double-blind study. Scientific Reports. 2015;5:13188. Source
  6. Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. Aviation, Space, and Environmental Medicine. 1995;66(4):313–319. Source
  7. Majeed M, Nagabhushanam K, Natarajan S, et al. Efficacy and safety of 1% forskolin eye drops in open angle glaucoma — an open label study. Saudi Journal of Ophthalmology. 2015;29(3):197–200. Source
  8. Bigagli E, Cinci L, D’Ambrosio M, et al. Pharmacological activities of an eye drop containing Matricaria chamomilla and Euphrasia officinalis extracts in UVB-induced oxidative stress and inflammation of human corneal cells. Journal of Photochemistry and Photobiology B. 2017;173:618–625. Source
  9. Yu P, Dong WP, Tang YB, et al. Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR. Annals of Translational Medicine. 2021;9(4):332. Source
  10. Wang R, Tang XC. Neuroprotective effects of huperzine A: a natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals. 2005;14(1–2):71–82. Source
  11. Sofi F, Marcucci R, Bolli P, et al. Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis. 2008;198(1):223–227. Source
  12. Jackson CR, Ruan GX, Aseem F, et al. Retinal dopamine mediates multiple dimensions of light-adapted vision. Journal of Neuroscience. 2012;32(27):9359–9368. Source
  13. Zhao ZC, Zhou Y, Tan G, et al. Research progress about the effect and prevention of blue light on eyes. International Journal of Ophthalmology. 2018;11(12):1999–2003. Source
  14. Thoreson WB, Witkovsky P. Glutamate receptors and circuits in the vertebrate retina. Progress in Retinal and Eye Research. 1999;18(6):765–810. Source
  15. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology. 2001;119(10):1417–1436. Source
  16. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. Source
  17. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Progress in Retinal and Eye Research. 2005;24(1):87–138. Source
  18. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. The Ocular Surface. 2017;15(3):334–365. Source
  19. Rosenfield M. Computer vision syndrome: a review of ocular causes and potential treatments. Ophthalmic and Physiological Optics. 2011;31(5):502–515. Source
  20. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. The Lancet. 2012;379(9827):1739–1748. Source
  21. Holmes JM, Lazar EL, Melia BM, et al. Effect of age on response to amblyopia treatment in children. Archives of Ophthalmology. 2011;129(11):1451–1457. Source
  22. GBD 2019 Blindness and Vision Impairment Collaborators. Trends in prevalence of blindness and distance and near vision impairment over 30 years. The Lancet Global Health. 2021;9(2):e130–e143. Source
  23. Chang AM, Aeschbach D, Duffy JF, Czeisler CA. Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness. PNAS. 2015;112(4):1232–1237. Source
  24. Topo E, Soricelli A, Di Maio A, et al. Evidence for the involvement of D-aspartic acid in learning and anxiety behaviors. Frontiers in Psychology. 2016;7:1915. Source
  25. National Institutes of Health, Office of Dietary Supplements. Niacin — fact sheet for health professionals. Source
  26. National Institutes of Health, Office of Dietary Supplements. Vitamin B6 — fact sheet for health professionals. Source
  27. U.S. Food and Drug Administration. Dietary Supplements: guidance and regulatory information (DSHEA). Source
  28. U.S. Food and Drug Administration. Dietary supplement labeling guide. Source
  29. National Eye Institute. Age-related macular degeneration (AMD). Source
  30. National Eye Institute. Dry eye. Source
  31. National Eye Institute. Diabetic retinopathy. Source
  32. National Eye Institute. Glaucoma. Source
  33. National Eye Institute. Cataracts. Source
  34. National Eye Institute. Amblyopia (lazy eye). Source
  35. National Eye Institute. Refractive errors. Source
  36. American Optometric Association. Computer vision syndrome. Source
  37. BrightFocus Foundation. Macular degeneration research overview. Source

Links open in a new tab. Citations are provided for ingredient and background research only. No published trial has tested the finished EyeFortin formula.

How to read a citation here

A citation supports a claim about an ingredient or a condition — not a claim about the product. Where we discuss what a study found, we name the population and the route of administration, because a trial of forskolin eye drops in glaucoma says nothing about a swallowed root extract. Our evidence policy explains the standard.

Reference gaps

Notably absent: any product-level clinical trial, any certificate of analysis, and any published pharmacokinetic data for this formula. Those absences are reported throughout the site rather than glossed over.